Two of the three members of this trio already have announced positive news developments that have given their shares big lifts.
The shares look attractive but timing is important.
The shares are poised to test the $255-$260 area again.
Once M&A activity picks up, I could see the biotech sector easily rallying 20% or more.
Here's our trading strategy for the shares.
The Fed as a whole needs to get their act together. Probably, it would be far better if these folks just piped the heck down.
Let's take a look at the charts and indicators.
Let's review the charts and indicators of MSOS.
BIIB shares have jumped around 50% in early trading activity Wednesday.
Plus, we take looks at Eli Lilly and Raytheon Technologies after positive news developments for both companies.